Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of the CYP2C19 Genetic Polymorphism on Gastritis, Peptic Ulcer Disease, Peptic Ulcer Bleeding and Gastric Cancer

  • Published : 2015.01.22
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The CYP2C19 genotype has been found to be an important factor for peptic ulcer healing and H. pylori eradication, influencing the efficacy of proton pump inhibitors (PPIs) and the pathogenesis of gastric cancer. The aim of this study was to investigate clinical correlations of the CYP2C19 genotype in patients with gastritis, peptic ulcer disease (PUD), peptic ulcer bleeding (PUB) and gastric cancer in Thailand. Materials and Methods: Clinical information, endoscopic findings and H. pylori infection status of patients were assessed between May 2012 and November 2014 in Thammasat University Hospital, Thailand. Upper GI endoscopy was performed for all patients. Five milliliters of blood were collected for H. pylori serological diagnosis and CYP2C19 study. CYP2C19 genotypes were determined by polymerase chain reaction (PCR) and restriction fragment length polymorphism analysis (RFLP) and classified as rapid metabolizer (RM), intermediate metabolizer (IM) or poor metabolizer (PM). Results: A total of 202 patients were enrolled including 114 with gastritis, 36 with PUD, 50 with PUB and 2 with gastric cancer. Prevalence of CYP2C19 genotype was 82/202 (40.6%) in RM, 99/202 (49%) in IM and 21/202 (10.4%) in PM. Overall H. pylori infection was 138/202 patients (68.3%). H. pylori infection was demonstrated in 72% in RM genotype, 69.7% in IM genotype and 47.6% in PM genotype. Both gastric cancer patients had the IM genotype. In PUB patients, the prevalence of genotype RM (56%) was highest followed by IM (32%) and PM(12%). Furthermore, the prevalence of genotype RM in PUB was significantly greater than gastritis patients (56% vs 36%: p=0.016; OR=2.3, 95%CI=1.1-4.7). Conclusions: CYP2C19 genotype IM was the most common genotype whereas genotype RM was the most common in PUB patients. All gastric cancer patients had genotype IM. The CYP2C19 genotype RM might be play role in development of PUD and PUB. Further study in different population is necessary to verify clinical usefulness of CYP2C19 genotyping in development of these upper GI diseases.

Keywords

References

  1. Bai L, He J, He GH, et al (2014). Association of CYP2C19 polymorphisms with survival of breast cancer patients using tamoxifen: results of a meta- analysis. Asian Pac J Cancer Prev, 15, 8331-5 https://doi.org/10.7314/APJCP.2014.15.19.8331
  2. Barkun AN, Bardou M, Kuipers EJ, et al (2010). International consensus upper gastrointestinal bleeding conference group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med, 152, 101-13. https://doi.org/10.7326/0003-4819-152-2-201001190-00009
  3. Chanagune S, Siramolpiwat S, Wongcha-um A, et al (2014). Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand. Asian Pac J Cancer Prev, 15, 9909-13. https://doi.org/10.7314/APJCP.2014.15.22.9909
  4. Chen J, Zheng X, Liu DY, et al (2014). Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients. Asian Pac J Cancer Prev, 15, 7195-200. https://doi.org/10.7314/APJCP.2014.15.17.7195
  5. Estany-Gestal A, Salgado-Barreira A, Sanchez-Diz P, et al (2011). Influence of CYP2C9 genetic variants on gastrointestinal anti-inflammatory drugs: a systematic critical review. Pharmacogenet Genomics, 21, 357-364. https://doi.org/10.1097/FPC.0b013e328346d2bb
  6. Furuta T, Graham DY (2010). Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol Clin North Am, 39, 465-80. https://doi.org/10.1016/j.gtc.2010.08.007
  7. Furuta T, Iwaki T, Umemura K (2010). Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol, 70, 383-92. https://doi.org/10.1111/j.1365-2125.2010.03717.x
  8. Furuta T, Shirai N, Takashima M, et al (2001). Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther, 69, 158-68. https://doi.org/10.1067/mcp.2001.113959
  9. McNicholl AG, Linares PM, Nyssen OP, et al (2012). Meta-analysis: esomeprazole or rabeprazole. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther, 36, 414-25. https://doi.org/10.1111/j.1365-2036.2012.05211.x
  10. Musumba CO, Jorgensen A, Sutton L, et al (2013). CYP2C19*17 Gain-of-function polymorphism is associated with peptic ulcer disease. Clin Pharmacol Ther, 93, 195-203. https://doi.org/10.1038/clpt.2012.215
  11. Musumba C, Pritchard DM, Pirmohamed M (2009). Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers. Aliment Pharmacol Ther, 30, 517-31. https://doi.org/10.1111/j.1365-2036.2009.04086.x
  12. Prasertpetmanee S, Mahachai V, Vilaichone RK (2013). Improved efficacy of proton pump inhibitor - amoxicillin-clarithromycin triple therapy for helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy. Helicobacter, 18, 270-3. https://doi.org/10.1111/hel.12041
  13. Shi WX, Chen SQ (2004). Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. World J Gastroenterol, 10, 1961-3. https://doi.org/10.3748/wjg.v10.i13.463
  14. Sugimoto M, Graham DY (2009). High-dose versus standard-dose PPI in triple therapy for Helicobacter pylori eradication. Nat Clin Pract Gastroenterol Hepatol, 6, 138-9.
  15. Sugimoto M, Furuta T, Shirai N, et al (2005). Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection. Aliment Pharmacol Ther, 22, 1033-40. https://doi.org/10.1111/j.1365-2036.2005.02678.x
  16. Vannarath S, Vilaichone RK, Rasachak B, et al (2014). Virulence genes of Helicobacter pylori in gastritis, peptic ulcer and gastric cancer in Laos. Asian Pac J Cancer Prev, 15, 9027-31. https://doi.org/10.7314/APJCP.2014.15.20.9027
  17. Vilaichone RK, Panarat W, Aekpongpaisit S, et al (2014). Clinical characteristics and Helicobacter pylori status of gastric cancer in Thailand. Asian Pac J Cancer Prev, 15, 9005-8. https://doi.org/10.7314/APJCP.2014.15.20.9005
  18. Xie HG, Stein CM, Kim RB, et al (1999). Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics, 9, 539-49.
  19. Yamada S, Onda M, Kato S, et al (2001). Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol, 36, 669-72. https://doi.org/10.1007/s005350170029

Cited by

  1. eradication vol.22, pp.1, 2016, https://doi.org/10.1111/hel.12324
  2. and Voriconazole Therapy vol.102, pp.1, 2017, https://doi.org/10.1002/cpt.583